title: CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.
abstract: BACKGROUND
  No biological or molecular marker of primary melanoma tumor cells has been shown to predict clinical outcome in melanoma.
  
  
  OBJECTIVE
  To determine whether CD10, CD133, nestin and CD20 may evaluate the prognosis of melanoma.
  
  
  METHODS
  The differential expression of these molecules was assessed in pairs of cell lines. We evaluated, by both immunohistochemical staining and RT-qPCR, their expression in a cohort of 32 patients (68 samples) with a history of metastatic melanoma, divided into two groups according to their clinical outcome profile.
  
  
  RESULTS
  CD10 over expression in cancer cell lines was associated with more aggressive behavior in vitro. A CD10-positive staining was more frequent in patients in the "rapidly progressive" group than those in the "long survivor" group (23/35 versus 2/18, p<10(-4)). CD10 expression was associated with a lower median overall survival (1.15 year - IQR: [0.50-2.58] versus 4.27 - IQR: [1.66-6.33]; p=10(-4)). The Odds Ratio of displaying a "rapidly progressive" melanoma when tumor cells expressed CD10 was 15 (95% confidence interval: [3-78]). After adjusting for confounding factors, CD10 expression in melanoma tumor cells remained associated with an increased risk of death and more rapid disease progression (p=6×10(-4); HR=3.71).
  
  
  CONCLUSIONS
  CD10 may predict clinical outcome in melanoma patients.
authors.affiliation: mariannethomas@ymail.com
authors.forename: Marianne
authors.initials: M
authors.lastname: Thomas-Pfaab
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Annereau
authors.forename: Coline
authors.initials: C
authors.lastname: Munsch
authors.forename: Nicolas
authors.initials: N
authors.lastname: Guilbaud
authors.forename: Ignacio
authors.initials: I
authors.lastname: Garrido
authors.forename: Carle
authors.initials: C
authors.lastname: Paul
authors.forename: Pierre
authors.initials: P
authors.lastname: Brousset
authors.forename: Laurence
authors.initials: L
authors.lastname: Lamant
authors.forename: Nicolas
authors.initials: N
authors.lastname: Meyer
mesh_terms: D000071916:AC133 Antigen; D000368:Aged; D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D018951:Antigens, CD20 / Q000235:genetics / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D018450:Disease Progression; D005260:Female; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000556:secondary*; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D015260:Neprilysin / Q000235:genetics* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D064231:Nestin; D010455:Peptides / Q000235:genetics / Q000378:metabolism; D011237:Predictive Value of Tests; D011379:Prognosis; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018951:Antigens, CD20; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; C577485:Nes protein, mouse; D064231:Nestin; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse; D015260:Neprilysin